Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05970302
Other study ID # NCC-009591
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 7, 2023
Est. completion date July 2026

Study information

Verified date July 2023
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy,in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a "hot tumor" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date July 2026
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically confirmed initially unresectable MSS/pMMR-type RAS-mutant metastatic colorectal adenocarcinoma; 2. ECOG score of 0 or 1; 3. Ability to swallow oral medications; 4. Have at least one measurable lesion (according to RECIST v1.1 standard); 5. No anti-tumor treatment has been received after recurrence and metastasis; 6. Neoadjuvant or adjuvant chemotherapy containing fluorouracil drugs is allowed before or after radical resection of colorectal cancer, but the treatment needs to be completed for = 6 months; if oxaliplatin is used in neoadjuvant or adjuvant chemotherapy, it includes The oxaliplatin regimen needs to be completed for =12 months; 7. Adequate organ function: On the premise of no component blood transfusion within 14 days: white blood cells = 3.5*10^9/L and neutrophils = 1.5*10^9/L, hemoglobin = 90g/L, platelets = 100* 10^9/L; serum bilirubin = 1.5 times the normal value, alanine aminotransferase (ALT) = 2.5 times the normal value, aspartate aminotransferase (AST) = 2.5 times the normal value; Urinary protein <2+. Or urine protein 2+ but 24-hour urine protein quantity = 1 g; serum creatinine = 1.5 times of normal value, creatinine clearance rate = 60ml/min; Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) = lower limit of normal value (50%); 8. Expected survival period = 3 months; 9. Patients fully understand this research, voluntarily participate in this clinical trial and sign an informed consent; 10. Women with reproductive potential (< 2 years after the last menstrual period) and men use effective contraceptive methods until half a year after the last treatment. Exclusion Criteria: 1. Previously received bevacizumab or anti-CTLA4, anti-PD-1/PD-L1 therapeutic antibodies or pathway-targeted drugs; 2. Received radiotherapy within 4 weeks before the evaluation; 3. Symptomatic peripheral neuropathy > grade 2 (CTCAE5.0 standard); 4. Received live vaccine or systemic immune stimulant (including but not limited to interferon or interleukin 2) within 1 month; 5. HIV-positive and other immunodeficiency diseases; 6. Active hepatitis B or hepatitis C (except for those who have been infected or cured before, that is, HBsAg negative and hepatitis B core antigen anti-HBc antibody positive; except for hepatitis C patients whose HCV RNA is negative by PCR); 7. Existing autoimmune diseases or other diseases that require immunosuppressant treatment, except for type 1 diabetes; except for hypothyroidism that only requires hormone replacement therapy; skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, alopecia areata); inhaled or topical steroids or equivalent steroids in excess of 10 mg prednisone per day, except for inactive autoimmune disease on adrenal replacement therapy; 8. Received systemic hormone therapy or treatment with a daily dose of more than 10 mg prednisone equivalent dose or other forms of immunosuppressive treatment within 7 days, but inhaled or topical steroids or daily application of more than 10 mg prednisone, etc. Except for inactive autoimmune diseases treated with adrenal replacement therapy with potent steroids; 9. Have a history of organ transplantation; 10. Uncontrolled central nervous system (CNC) metastasis (symptomatic or metastatic sites are midbrain, pons, medulla or spinal cord) or other central nervous system diseases; 11. Those who have undergone major surgery, open biopsy or obvious traumatic trauma within 1 month, or who may need major surgery during the study period; those who have undergone open biopsy or obvious traumatic trauma, or may need major surgery during the study period; 12. Combined with other malignant tumors other than intestinal cancer (except cured basal cell carcinoma or squamous cell carcinoma of the skin and carcinoma in situ of the cervix; the treatment of other malignant tumors has been completed for more than 1 year, and there is no clinical and imaging evidence of recurrence or progression except); 13. Combined active and refractory infection; 14. Cardiovascular diseases with clinical significance, such as cardiovascular accident (CVA) (= 6 months before treatment), myocardial infarction (= 6 months before treatment), unstable angina, chronic heart failure of NYHA = 2 (CHF), uncontrolled arrhythmia; uncontrolled hypertension; thromboembolic or bleeding events within 6 months before treatment; 15. Evidence of causing coagulation disease; 16. With dysphagia, active peptic ulcer, complete or incomplete intestinal obstruction, active gastrointestinal bleeding, perforation, malabsorption syndrome or uncontrollable gastrointestinal inflammatory disease (such as Crohn's disease or ulcerative colon inflammation); 17. Severe unhealed wounds/ulcers or severe fractures; 18. Any serious acute or chronic medical condition that may affect the patient's participation in the study or interfere with the interpretation of the study results; 19. There are mental illnesses, serious social and psychological illnesses, or researchers believe that there are factors that may affect research compliance; 20. Pregnant or lactating women; 21. No therapeutic anticoagulant or antiplatelet drugs or NSAIDs (aspirin = 325 mg/day allowed); 22. Severe allergic reaction to the test drug; 23. Reluctance to use alternative therapies such as (but not limited to) bisphosphonates if receiving RANKL inhibitors (eg, denosumab).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine
Use the above medications on a regular basis.

Locations

Country Name City State
China Lin Yang Beijing

Sponsors (1)

Lead Sponsor Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) ORR of regimen of XELOX +Bev +Tislelizumab 2 years
Secondary Duration of Response (DoR) 2 years
Secondary Disease Control Rate (DCR); 2 years
Secondary Median Progression-Free Survival (mPFS) 2 years
Secondary 12-month PFS rate 12 months
Secondary Median Overall Survival (mOS) 5 years
Secondary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Adverse Events (AEs) Incidence, Serious Adverse Events (SAE) Incidence 2 years
See also
  Status Clinical Trial Phase
Completed NCT03079440 - TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors Phase 2
Completed NCT03079427 - Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT05290194 - Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT03889626 - The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Phase 3
Recruiting NCT06169202 - A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
Not yet recruiting NCT05841134 - Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer Phase 2
Recruiting NCT05022030 - First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes Phase 2
Recruiting NCT06202014 - Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC Phase 2
Enrolling by invitation NCT03030508 - Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients N/A
Recruiting NCT02012634 - Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Phase 3
Active, not recruiting NCT06188000 - Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine N/A
Completed NCT06246461 - The Therapeutic Effect of Different Doses of Capecitabine N/A
Completed NCT04720131 - Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. Phase 2
Active, not recruiting NCT03258099 - Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Recruiting NCT05535413 - UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases Phase 1/Phase 2
Active, not recruiting NCT03500380 - A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases Phase 2/Phase 3
Recruiting NCT06405490 - NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Phase 2